Apolipoprotein D expression in substantia nigra of Parkinson disease

被引:0
|
作者
Ordoñez, C
Navarro, A
Perez, C
Astudillo, A
Martínez, E
Tolivia, J
机构
[1] Univ Oviedo, Fac Biol & Med, Dept Morfol & Biol Celular, E-33006 Oviedo, Spain
[2] Hosp Cent Asturias, Serv Anat Pathol, Oviedo, Spain
关键词
apo D; dopaminergic neurons; glial cells; immunohistochemistry; neuromelanin;
D O I
暂无
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Apolipoprotein D (apo D), a lipocalin transporter of small hydrophobic molecules could play an important role in several neurodegenerative diseases. However, its role in those diseases remains unclear. Increments of apo D have been reported in relation with injury and degeneration in the nervous system. Recently increases of apo D level have been reported in schizophrenia, a neuropathologic disease where the oxidative stress and lipid abnormalities may be involved. Apo D could act as a sequestering molecule binding excess of arachidonic acid in cells. In order to determine the relationship between apo D expression and other neurodegenerative pathologies related to oxidative damage, we studied the presence of apo D in the substantia nigra of control and Parkinson disease (PD) subjects. We found dopaminergic neurons were not immunoreactive for apo D,. control or PD subjects. However, surrounding glial cells showed immunostaining for apo D and signal increases in PD cases. These findings support the role of apolipoprotein D in neuroprotection and the importance of glia in the amount of this protein in the central nervous system.
引用
收藏
页码:361 / 366
页数:6
相关论文
共 50 条
  • [41] The substantia nigra echogenity in Parkinson's disease -: A pilot study
    Ressner, P.
    Skoloudik, D.
    Kanovsky, P.
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2006, 69 (05) : 376 - 379
  • [42] An altered histaminergic innervation of the substantia nigra in Parkinson's disease
    Anichtchik, OV
    Rinne, JO
    Kalimo, H
    Panula, P
    EXPERIMENTAL NEUROLOGY, 2000, 163 (01) : 20 - 30
  • [43] Copper pathology in the vulnerable substantia nigra in Parkinson's disease
    Davies, K. M.
    Bohic, S.
    Ortega, R.
    Cottam, V.
    Hare, D. J.
    Finberg, J. P. M.
    Halliday, G.
    Mercer, J. F. B.
    Double, K. L.
    MOVEMENT DISORDERS, 2013, 28 : S366 - S366
  • [44] Transcranial sonography of the substantia nigra in patients with Parkinson's disease
    Miwa, Hideto
    Okawa, Masae
    Kajimoto, Yoshinori
    Kondo, Tomoyoshi
    JOURNAL OF NEUROLOGY, 2007, 254 (Suppl 4) : 15 - 20
  • [45] Substantia nigra hyperechogenicity in Mexican patients with Parkinson's disease
    Rodriguez-Garza, C. Y.
    Anaya-Escamilla, A.
    Pinales-Razo, R.
    Estrada-Bellmann, I.
    Camara-Lemarroy, C. R.
    MOVEMENT DISORDERS, 2016, 31 : S436 - S436
  • [46] Patterns of cell loss in the substantia nigra in Parkinson's disease
    Damier, P
    Hirsch, EC
    Agid, Y
    Graybiel, AM
    NEUROLOGY, 1996, 46 (02) : 6045 - 6045
  • [47] Quantitative Susceptibility Mapping of the Substantia Nigra in Parkinson’s Disease
    Xinxin Zhao
    Hedi An
    Tian Liu
    Nan Shen
    Binshi Bo
    Zhuwei Zhang
    Pengfei Weng
    Meining Chen
    Mengchao Pei
    Yi Wang
    Dongya Huang
    Jianqi Li
    Applied Magnetic Resonance, 2017, 48 : 533 - 544
  • [48] Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease
    Pearce, RKB
    Owen, A
    Daniel, S
    Jenner, P
    Marsden, CD
    JOURNAL OF NEURAL TRANSMISSION, 1997, 104 (6-7) : 661 - 677
  • [49] Ultrasonography of substantia nigra in Japanese patients with Parkinson's disease
    Okawa, M.
    Kajimoto, Y.
    Miwa, H.
    Kondo, T.
    MOVEMENT DISORDERS, 2006, 21 : S500 - S500
  • [50] Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease
    Hochstrasser, H
    Bauer, P
    Walter, U
    Behnke, S
    Spiegel, J
    Csoti, I
    Zeiler, B
    Bornemann, A
    Pahnke, J
    Becker, G
    Riess, O
    Berg, D
    NEUROLOGY, 2004, 63 (10) : 1912 - 1917